Astellas and Basilea have been boosted by the news that advisors to the US Food and Drug Administration have recommended their antifungal Cresemba.

The agency’s Anti-Infective Drugs Advisory Committee voted unanimously (11-0) to recommend approval of once-daily intravenous and oral broad-spectrum Cresemba (isavuconazole) for the treatment of invasive aspergillosis. The second vote was 8 to 2 (with one abstention) to back the drug for treatment of invasive mucormycosis, also known as zygomycosis. The two are life-threatening fungal infections predominantly occurring in immunocompromised patients.

Astellas expects the FDA, which granted orphan drug designation to Cresemba in November, to make its final decision by March 8. The therapy will compete against Pfizer’s Vfend (voriconazole).

Basilea holds full rights to Cresemba in markets outside the USA and Canada and it expects a European regulatory review to be completed by the fourth quarter of 2015.